StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
NORDH.OL$26.20-3.68%
Fair $26.20+0.0%

NORDH.OL

Nordhealth AS

Healthcare / Health Information ServicesOslo

$26.20

-1.00 (-3.68%)

Fairly Valued+0.0%Fair Value $26.20Fund rank 25/100 · Data gapFallback financials|
SA 17/F
F-Score: 3/9
Low Profitability

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 34% · confianza 19%

FCF escenarios

weak_data · normalized FCF $-4.4M · quality 47.7/100

Data gap 25/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 29/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

17/100

F

Piotroski

3/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

16/100

SEC 0%

Latest source: unknownPeriods: 4Warnings: 1unknown: 4
No SEC-backed annual rows; valuation uses fallback financial data. Insufficient audited annual history (<3 SEC-backed years); composite fair value and forward targets are disabled until manually verified. ROE is -20.6%, below the 5% threshold
Thesis & Journal · NORDH.OLLocal privado en este navegador · Nordhealth AS
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$2.1B

P/E

N/A

•

EV/EBITDA

N/A

•

ROE

-20.6%

↓

Gross Margin

81.2%

↑

Debt/Equity

N/A

•
52-Week Range$26
$21$41

TradingView lightweight chart

NORDH.OL price, volumen y niveles de valoración

Último $26.20Periodo -32.8%
Fair value: $26.20

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2022–2025 · 3 años de histórico normalizado

Revenue CAGR

+17.9%

FCF CAGR

—

FCF margin

-8.6%

FCF / Net income

0.34x

Latest source

Provider fallback

Margin decomposition

Último año: revenue $50.8M · net income $-12.7M · FCF $-4.4M

2022-FY → 2025-FY

Gross margin

81.2%-3.4% pts

Operating margin

-24.5%+22.8% pts

Net margin

-24.9%+21.0% pts

FCF margin

-8.6%+33.6% pts
MetricTTM
2025
2024
2023
2022
Income Statement
Revenue$50.8M$50.8M$45.7M$36.8M$31.0M
Net Income$-12.7M$-12.7M$-7.7M$-11.1M$-14.3M
EBITDA$-965000.00$-965000.00$4.2M$-659000.00$-5.4M
EPS-0.16-0.16-0.10-0.14-0.18
Gross Margin81.2%81.2%85.4%86.0%84.6%
Operating Margin-24.5%-24.5%-16.9%-30.9%-47.3%
Net Margin-24.9%-24.9%-16.8%-30.2%-45.9%
Balance Sheet
Debt/Equity————0.00
Current Ratio1.661.66———
Cash Flow
Free Cash Flow$-4.4M$-4.4M$-3.2M$-10.9M$-13.1M
Returns
ROE-20.6%-20.6%-10.4%-13.4%-14.5%
Valuation
EV/EBITDA——800.19——
P/B33.5433.5445.8526.5516.26
Growth & Yield
Revenue Growth11.3%11.3%24.0%18.6%—
EPS Growth-65.8%-65.8%31.1%20.8%—

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%
Reverse DCF requires positive EPS; loss-making or zero-EPS companies cannot produce a clean EPS hurdle.

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · 1Y approxreconcilia total -30.3%

Total return

-30.3%

Start / end P/E

n/dx → n/dx

EPS bridge

-0.10 → -0.16

Residual

-30.3%

EPS growthn/d
Multiple reratingn/d
Dividend+0.0%
Residual / FX / buybacks / cross-term-30.3%

EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.

Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.